Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) EBITDA Margin (2016 - 2025)

Arcadia Biosciences filings provide 12 years of EBITDA Margin readings, the most recent being 70.37% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 7917.0% to 70.37% in Q4 2025 year-over-year; TTM through Dec 2025 was 10.07%, a 1917.0% increase, with the full-year FY2025 number at 10.11%, up 1915.0% from a year prior.
  • EBITDA Margin hit 70.37% in Q4 2025 for Arcadia Biosciences, up from 88.48% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 248.55% in Q1 2021 to a low of 313.88% in Q1 2023.
  • Median EBITDA Margin over the past 5 years was 90.26% (2021), compared with a mean of 53.07%.
  • The widest YoY moves for EBITDA Margin: up 344741bps in 2021, down -56828bps in 2021.
  • Arcadia Biosciences' EBITDA Margin stood at 215.3% in 2021, then surged by 134bps to 73.02% in 2022, then plummeted by -310bps to 153.54% in 2023, then soared by 94bps to 8.8% in 2024, then soared by 900bps to 70.37% in 2025.
  • The last three reported values for EBITDA Margin were 70.37% (Q4 2025), 88.48% (Q3 2025), and 34.43% (Q2 2025) per Business Quant data.